Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

NCT04990726 · clinicaltrials.gov ↗

ACTIVE_NOT_RECRUITING

Status

126

Enrollment

OTHER

Sponsor class

Conditions

Clinical Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage III Cutaneous Melanoma AJCC v8
Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Pathologic Stage IIID Cutaneous Melanoma AJCC v8
Melanoma, Stage II
Melanoma Stage IV

Interventions

BEHAVIORAL: Assessment
PROCEDURE: Biospecimen Collection
OTHER: Quality-of-Life Assessment
OTHER: Questionnaire Administration

Sponsor

M.D. Anderson Cancer Center